Abstract
MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression through post-transcriptional gene silencing. Since their discovery, miRNAs have emerged as key regulators of numerous biological processes and have been implicated in a wide range of human diseases, including liver cancer. Altered miRNA expression profiles have been associated with disease initiation, progression, therapeutic response, and clinical outcome, including in chronic liver diseases and hepatocellular carcinoma, where numerous dysregulated miRNAs have been proposed as therapeutic targets. Consequently, considerable efforts have focused on restoring downregulated tumor suppressor miRNAs using synthetic mimics or inhibiting oncogenic miRNAs with antisense oligonucleotides and related technologies. Despite encouraging preclinical results and substantial investment over the past two decades, the clinical translation of miRNA-based therapeutics has remained limited.In this review, we examine the biological and translational challenges that inherently limit therapeutic modulation of miRNAs in vivo. We discuss how the broad regulatory scope of individual miRNAs, their extensive target networks, context-dependent functions, functional redundancy, and the difficulty of achieving physiologically relevant modulation contribute to unpredictable therapeutic outcomes. Collectively, the available data suggests that although miRNAs remain invaluable biomarkers and powerful tools for understanding disease biology, the very biological properties that make them attractive regulators of cellular processes also represent fundamental challenges to their successful therapeutic application.

This publication has 52 references indexed in Scilit: